Truist lowered the firm’s price target on Medpace (MEDP) to $539 from $555 and keeps a Hold rating on the shares. The firm is updating its model after discussing the company’s Q4 results, cancellation trends, metabolic trial activity, revenue and margin details for 2026 with its management, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: